Metrics other than potency reveal systematic variation in responses to cancer drugs.
about
In vitro human cell line models to predict clinical response to anticancer drugsCell-to-cell variability in cell death: can systems biology help us make sense of it all?Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentQuantitative modeling of dose–response and drug combination based on pathway networkSynthesis, Characterization, and Study of In Vitro Cytotoxicity of ZnO-Fe3O4 Magnetic Composite Nanoparticles in Human Breast Cancer Cell Line (MDA-MB-231) and Mouse Fibroblast (NIH 3T3)Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical useA community effort to assess and improve drug sensitivity prediction algorithms.Enhancing reproducibility in cancer drug screening: how do we move forward?Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening.Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.An unbiased metric of antiproliferative drug effect in vitro.IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cellsDeconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.How Consistent are Publicly Reported Cytotoxicity Data? Large-Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements.Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.In vitro clinical trials: the future of cell-based profiling.Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells.Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targetsSevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signalingImmune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.Identifying genes that mediate anthracyline toxicity in immune cellsRadiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition.Fractional killing arises from cell-to-cell variability in overcoming a caspase activity thresholdThe DIONESUS algorithm provides scalable and accurate reconstruction of dynamic phosphoproteomic networks to reveal new drug targets.Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.Mitotic arrest of breast cancer MDA-MB-231 cells by a halogenated thieno[3,2-d]pyrimidine.Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method.An automated fitting procedure and software for dose-response curves with multiphasic features.Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.Cellular uptake and anticancer activity of carboxylated gallium corrolesUltrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting.Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias.Non-genetic diversity modulates population performance.Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.Surviving apoptosis: life-death signaling in single cells.
P2860
Q27000665-84733E7C-1E7B-45DF-83B5-B7CF6BFFB15BQ27013063-B4C62839-3E93-48C6-8DAF-62B4207DB2B6Q27313653-55A7350D-BD54-46C6-8699-EEEBCF883592Q27902294-CEA2DEF2-87D3-474E-ADB4-895739A93B34Q28395765-A4B13E74-278B-4561-97C3-967FC36AC6C6Q28541231-9AAEAEF5-B07B-4725-9DEE-5FDBB9035602Q30371323-80206088-181F-4F93-9B8D-B90E750885CCQ30405622-53CD3DD2-9DC8-4CCE-B25B-DA1E67642C98Q30422519-D6F65B51-9B7E-4A2E-8B91-BF2DD46EED98Q30436867-CE528941-F418-40EE-83A2-8B18B29F37B7Q30763539-15BA7544-B704-49E5-A1F4-FC4C42996A99Q30827658-0140063C-A4CB-40DD-9B76-E9EC50FC01E2Q30841629-A3D8ADD9-4D09-4B18-9891-B3B6318CCFEFQ31018677-599DA342-FDEF-47C2-A669-37FC441A3BC4Q31109155-C597ECB4-1A21-494F-BEAF-EEAB0C605D31Q33676812-53220824-AAF5-4C47-8889-C7C04B2E0B5BQ33898926-B3A3B35E-1EFF-4E6A-AD8D-890D398EB083Q33903831-24C818F3-5A10-4377-940B-86A25599BDE5Q34628699-18C807ED-185A-4173-A451-D21A301AFF59Q35425222-7B2090B3-E793-4F82-B390-F3CC9E0E4EF8Q35429116-024CAE41-EC0A-4ED5-BD0C-6C6BB4781DABQ35587475-29F65DCF-373C-4D3E-89D6-079B1A112C4AQ35705510-10A43254-6CC4-400C-923F-884A9DD051D9Q35878760-40273353-964F-41D9-A1A7-98718AE20D27Q36005156-91F84C35-2525-4674-8DE3-A8EC71D6679AQ36015911-B9620F55-98A7-4F70-8D18-79239394D978Q36070523-2A246454-995B-4BDA-B58D-0C6DB5BE4947Q36104106-5DCACE23-2C10-418C-B3CC-A0CC893B46FEQ36109688-9E684AD7-6717-4393-A22A-2BDE6D7A2887Q36311216-559A7D5B-6308-4208-9E82-633789285316Q36379132-29651D12-E8D5-4765-AEF4-D82ACC24E6ADQ36605057-C11EFAD9-EAC3-4A0D-AF6E-658879B7BBC4Q36831581-613D4DD2-0A02-4023-883C-AACDF4B861C7Q37019409-CD411593-1B87-48EA-8D17-225FFC2736B8Q37379676-B755F471-463D-4ACB-9139-7109BAD067D5Q37544655-6684D0A7-FFB9-45E2-976C-F1DE65FF4333Q37624658-AFDC4730-DC2D-4E3D-89B4-1243EA938A01Q37642614-384930E4-3483-418B-A964-0ED84E43D719Q37644414-1E600FB9-FC70-4FB8-B5B9-199B21813C36Q38446898-8B131C9C-B9A0-4E9D-88AA-ABE81E1A111F
P2860
Metrics other than potency reveal systematic variation in responses to cancer drugs.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@ast
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@en
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@nl
type
label
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@ast
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@en
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@nl
prefLabel
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@ast
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@en
Metrics other than potency reveal systematic variation in responses to cancer drugs.
@nl
P2860
P50
P356
P1476
Metrics other than potency reveal systematic variation in responses to cancer drugs
@en
P2093
Laura M Heiser
Mohammad Fallahi-Sichani
P2860
P2888
P304
P356
10.1038/NCHEMBIO.1337
P577
2013-09-08T00:00:00Z